Walleye Trading’s Iovance Biotherapeutics IOVA Stock Holding History

Walleye Trading’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$41.4K	Sell	9,944 -3,868	-28%	-$14.7K	﹤0.01%	3629
2026 Q1	$48.5K	Buy	13,812 +1,860	+16%	+$5.95K	﹤0.01%	3692
2025 Q4	$32.6K	Buy	+11,952	New	+$27.6K	﹤0.01%	4044
2025 Q1	–	Sell	-21,196	Closed	-$157K	–	4356
2024 Q4	$157K	Buy	+21,196	New	+$196K	﹤0.01%	3343
2024 Q1	–	Sell	-31,494	Closed	-$367K	–	5038
2023 Q4	$256K	Buy	31,494 +26,438	+523%	+$138K	﹤0.01%	3609
2023 Q3	$23K	Buy	+5,056	New	+$33K	﹤0.01%	4369
2022 Q3	–	Sell	-24,704	Closed	-$273K	–	5255
2022 Q2	$273K	Buy	+24,704	New	+$324K	﹤0.01%	3457
2022 Q1	–	Sell	-19,284	Closed	-$368K	–	5576
2021 Q4	$368K	Buy	19,284 +1,815	+10%	+$40K	﹤0.01%	3245
2021 Q3	$431K	Buy	17,469 +6,142	+54%	+$145K	﹤0.01%	3069
2021 Q2	$295K	Buy	11,327 +9,889	+688%	+$257K	﹤0.01%	3526
2021 Q1	$46K	Buy	+1,438	New	+$59.6K	﹤0.01%	4357
2020 Q2	–	Sell	-10,424	Closed	-$312K	–	4407
2020 Q1	$312K	Buy	+10,424	New	+$276K	﹤0.01%	2252

Other funds holding IOVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

MFM

MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Walleye Trading's IOVA Position: Q2 2026 in Review

Walleye Trading reduced its Iovance Biotherapeutics (IOVA) stake by 28% in Q2 2026, selling an estimated $14.7K and leaving 9,944 shares worth $41.4K. The position accounts for ﹤0.01% of the portfolio, ranked #3629.

Walleye Trading first reported a position in IOVA in Q1 2020 and has held it in 12 quarters since. The position peaked at $431K in Q3 2021. 292 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

Walleye Trading held 9,944 shares of Iovance Biotherapeutics worth $41.4K as of Q2 2026.
Walleye Trading sold 3,868 Iovance Biotherapeutics shares in Q2 2026, an estimated $14.7K.
Iovance Biotherapeutics made up ﹤0.01% of Walleye Trading's portfolio in Q2 2026, its #3629 holding.
Walleye Trading first reported a position in Iovance Biotherapeutics in Q1 2020 and has held it in 12 quarters since.
Walleye Trading's Iovance Biotherapeutics position peaked at $431K in Q3 2021.
292 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Walleye Trading's 13F filing for Q2 2026, filed 3 Aug 2026.